TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vigil Neuroscience Inc ( (VIGL) ) has issued an update.
On May 21, 2025, Vigil Neuroscience Inc. entered into a merger agreement with Sanofi, with Vigil becoming a wholly-owned subsidiary. Following this, from June 18 to July 28, 2025, Vigil received 16 demands from stockholders alleging omissions in the merger’s proxy statement. Vigil plans to defend against these demands but has voluntarily supplemented disclosures to avoid potential delays and expenses.
The most recent analyst rating on (VIGL) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Vigil Neuroscience Inc stock, see the VIGL Stock Forecast page.
Spark’s Take on VIGL Stock
According to Spark, TipRanks’ AI Analyst, VIGL is a Underperform.
Vigil Neuroscience Inc’s stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.
To see Spark’s full report on VIGL stock, click here.
More about Vigil Neuroscience Inc
Vigil Neuroscience Inc. operates in the biopharmaceutical industry, focusing on developing treatments for neurodegenerative diseases.
Average Trading Volume: 1,518,258
Technical Sentiment Signal: Buy
Current Market Cap: $383.9M
Find detailed analytics on VIGL stock on TipRanks’ Stock Analysis page.